Related Experiment Video

Updated: Jun 17, 2025

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

10.9K

Tetrahydroisoquinolines - an updated patent review for cancer treatment (2016 - present)

Ankur Kumar Tanwar1, Neha Sengar1, Nobuyuki Mase2

  • 1Departments of Natural Products, National Institute of Pharmaceutical Education and Research, S.A.S. Nagar, Mohali, India.

Expert Opinion on Therapeutic Patents
|August 10, 2024
PubMed
Abstract

Insights

Tetrahydroisoquinoline (THIQ) derivatives show promise as anticancer agents. This review covers THIQ-based cancer drug patents from 2016-2024, highlighting their therapeutic potential.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Drug Discovery

Background:

  • Cancer remains a leading global cause of mortality, driven by genetic and environmental factors.
  • Tetrahydroisoquinoline (THIQ) is a core structure in various alkaloids with known biological activities.
  • THIQ derivatives are integral to pharmacological processes and clinical research.

Purpose of the Study:

  • To review the therapeutic applications of tetrahydroisoquinoline (THIQ) derivatives as anticancer agents.
  • To analyze patents related to THIQ-based anticancer drugs from 2016 to 2024.
  • To identify promising THIQ analogues for future cancer drug development.

Main Methods:

  • Comprehensive patent searches were conducted using Espacenet, Google Patents, WIPO, and Sci Finder.
  • Patents covering THIQ derivatives with anticancer applications were identified and analyzed.
  • Therapeutic targets and efficacy data from the patents were examined.

Main Results:

  • Numerous THIQ compounds have been patented for their potential as anticancer agents.
  • These THIQ derivatives demonstrate significant efficacy against various cancer targets.
  • The development of multi-target ligands based on THIQ is a key area of focus.

Conclusions:

  • THIQ analogues represent a promising scaffold for the development of novel anticancer drugs.
  • Further research into THIQ-based multi-target ligands could lead to significant advancements in cancer therapy.
  • The patent landscape indicates continued innovation in THIQ-based oncology drug discovery.
Keywords:
1,2,3,4-tetrahydroisoquinolineBcl-xLCancerHPK1PRMT5anticancer agentscancer targets

More Related Videos

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts09:20

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

8.4K
Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches06:19

Author Spotlight: Exploring the Role of Ion Channels in Cancer: Characterization and Potential Treatment Approaches

Published on: June 16, 2023

3.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K